We are analyzing https://link.springer.com/article/10.1007/s11906-010-0125-3.

Title:
Inflammation and Therapy for Hypertension | Current Hypertension Reports
Description:
It is currently accepted that hypertension, atherosclerosis, and diabetes are disorders with subtle or overt activation of inflammatory mediators. Therefore, it has become increasingly important to ascertain whether current antihypertensive drug families have proinflammatory or anti-inflammatory actions that modify the outcomes of their hemodynamic effects on blood pressure. We review the current state of knowledge about the effects of the major classes of available antihypertensive agents on inflammation and speculate on the possible contribution of these effects to observations in clinical trials. We suggest that a strategy of drug development specifically addressing inflammation in hypertension may provide increased benefit in terms of target organ damage, and we describe some examples of these promising developments.
Website Age:
28 years and 1 months (reg. 1997-05-29).

Matching Content Categories {📚}

Health & Fitness
Education
Science

Content Management System {📝}

What CMS is link.springer.com built with?

Custom-built

No common CMS systems were detected on Link.springer.com, and no known web development framework was identified.

Traffic Estimate {📈}

What is the average monthly size of link.springer.com audience?

🌠 Phenomenal Traffic: 5M - 10M visitors per month

Based on our best estimate, this website will receive around 5,000,019 visitors per month in the current month.
However, some sources were not loaded, we suggest to reload the page to get complete results.

check SE Ranking
check Ahrefs
check Similarweb
check Ubersuggest
check Semrush

How Does Link.springer.com Make Money? {💸}

We can't tell how the site generates income.

Not all websites focus on profit; some are designed to educate, connect people, or share useful tools. People create websites for numerous reasons. And this could be one such example. Link.springer.com might be cashing in, but we can't detect the method they're using.

Keywords {🔍}

article, google, scholar, cas, pubmed, hypertension, effects, rats, renal, inflammation, blood, patients, heart, angiotensin, hypertensive, receptor, pressure, hypertens, inflammatory, res, calcium, effect, endothelial, laffer, elijovich, antihypertensive, cardiac, vascular, oxidative, stress, therapy, treatment, amlodipine, cells, expression, human, blocker, endothelin, essential, function, diabetes, activation, study, kidney, evaluation, failure, int, pharmacol, channel, blockers,

Topics {✒️}

ikk-beta/i-kappab/nf-kappab axis calcium channel blockers month download article/chapter mineralocorticoid receptor–dependent mechanism selective endothelin-receptor antagonist renin-angiotensin system inhibitors agents exhibit anti-inflammatory angiotensin ii-infused rats aldosterone-induced oxidative stress renin-angiotensin system antagonists diet-induced insulin resistance valsartan antihypertensive long-term nuclear transcription factor-kappab calcium channel blocker beta-receptor activation participate l-type ca2+ channels smoking-induced endothelial dysfunction l-type ca2+ antagonist transcription factor nf-kappa tumor necrosis factor-alpha anti-oxidative stress actions β-blockers remain vasodilating beta-blocker nebivolol chronic heart failure low-renin essential hypertension low-aldosterone hypertensive rats salt-sensitive essential hypertension beta-blockers antihypertensive agents angiotensin iv activates myocardial infarction treated fixed-dose combination therapies blood pressure-lowering drugs at1 receptor expression suppress superoxide production cardiomyocyte ang ii spironolactone decreases expression beta-blocker therapy blood pressure-lowering actions related subjects full article pdf anti-atherosclerotic effects independent lercanidipine prevents hyperpolarization reduce blood pressure endothelin-receptor antagonist direct renin inhibition nf-kappab activity at1 receptor blocker heart failure–assessment anti-hypertensive drug

Questions {❓}

Should β-blockers remain first choice in the treatment of primary hypertension?

Schema {🗺️}

WebPage:
      mainEntity:
         headline:Inflammation and Therapy for Hypertension
         description:It is currently accepted that hypertension, atherosclerosis, and diabetes are disorders with subtle or overt activation of inflammatory mediators. Therefore, it has become increasingly important to ascertain whether current antihypertensive drug families have proinflammatory or anti-inflammatory actions that modify the outcomes of their hemodynamic effects on blood pressure. We review the current state of knowledge about the effects of the major classes of available antihypertensive agents on inflammation and speculate on the possible contribution of these effects to observations in clinical trials. We suggest that a strategy of drug development specifically addressing inflammation in hypertension may provide increased benefit in terms of target organ damage, and we describe some examples of these promising developments.
         datePublished:2010-06-04T00:00:00Z
         dateModified:2010-06-04T00:00:00Z
         pageStart:233
         pageEnd:242
         sameAs:https://doi.org/10.1007/s11906-010-0125-3
         keywords:
            Hypertension
            Antihypertensive agents
            Inflammation
            Oxidative stress
            Cytokines
            Thiazides
            Mineralocorticoid receptor blockers
            Beta-blockers
            Calcium channel blockers
            Blockers of the renin-angiotensin system
            Endothelin receptor blockers
            Internal Medicine
            Cardiology
            Metabolic Diseases
            Nephrology
            Primary Care Medicine
            General Practice / Family Medicine
         image:
         isPartOf:
            name:Current Hypertension Reports
            issn:
               1534-3111
               1522-6417
            volumeNumber:12
            type:
               Periodical
               PublicationVolume
         publisher:
            name:Current Science Inc.
            logo:
               url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
               type:ImageObject
            type:Organization
         author:
               name:Cheryl L. Laffer
               affiliation:
                     name:Scott & White Memorial Hospital and Clinics
                     address:
                        name:Scott & White Memorial Hospital and Clinics, Temple, USA
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Fernando Elijovich
               affiliation:
                     name:Scott & White Memorial Hospital and Clinics
                     address:
                        name:Scott & White Memorial Hospital and Clinics, Temple, USA
                        type:PostalAddress
                     type:Organization
               email:[email protected]
               type:Person
         isAccessibleForFree:
         hasPart:
            isAccessibleForFree:
            cssSelector:.main-content
            type:WebPageElement
         type:ScholarlyArticle
      context:https://schema.org
ScholarlyArticle:
      headline:Inflammation and Therapy for Hypertension
      description:It is currently accepted that hypertension, atherosclerosis, and diabetes are disorders with subtle or overt activation of inflammatory mediators. Therefore, it has become increasingly important to ascertain whether current antihypertensive drug families have proinflammatory or anti-inflammatory actions that modify the outcomes of their hemodynamic effects on blood pressure. We review the current state of knowledge about the effects of the major classes of available antihypertensive agents on inflammation and speculate on the possible contribution of these effects to observations in clinical trials. We suggest that a strategy of drug development specifically addressing inflammation in hypertension may provide increased benefit in terms of target organ damage, and we describe some examples of these promising developments.
      datePublished:2010-06-04T00:00:00Z
      dateModified:2010-06-04T00:00:00Z
      pageStart:233
      pageEnd:242
      sameAs:https://doi.org/10.1007/s11906-010-0125-3
      keywords:
         Hypertension
         Antihypertensive agents
         Inflammation
         Oxidative stress
         Cytokines
         Thiazides
         Mineralocorticoid receptor blockers
         Beta-blockers
         Calcium channel blockers
         Blockers of the renin-angiotensin system
         Endothelin receptor blockers
         Internal Medicine
         Cardiology
         Metabolic Diseases
         Nephrology
         Primary Care Medicine
         General Practice / Family Medicine
      image:
      isPartOf:
         name:Current Hypertension Reports
         issn:
            1534-3111
            1522-6417
         volumeNumber:12
         type:
            Periodical
            PublicationVolume
      publisher:
         name:Current Science Inc.
         logo:
            url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
            type:ImageObject
         type:Organization
      author:
            name:Cheryl L. Laffer
            affiliation:
                  name:Scott & White Memorial Hospital and Clinics
                  address:
                     name:Scott & White Memorial Hospital and Clinics, Temple, USA
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Fernando Elijovich
            affiliation:
                  name:Scott & White Memorial Hospital and Clinics
                  address:
                     name:Scott & White Memorial Hospital and Clinics, Temple, USA
                     type:PostalAddress
                  type:Organization
            email:[email protected]
            type:Person
      isAccessibleForFree:
      hasPart:
         isAccessibleForFree:
         cssSelector:.main-content
         type:WebPageElement
["Periodical","PublicationVolume"]:
      name:Current Hypertension Reports
      issn:
         1534-3111
         1522-6417
      volumeNumber:12
Organization:
      name:Current Science Inc.
      logo:
         url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
         type:ImageObject
      name:Scott & White Memorial Hospital and Clinics
      address:
         name:Scott & White Memorial Hospital and Clinics, Temple, USA
         type:PostalAddress
      name:Scott & White Memorial Hospital and Clinics
      address:
         name:Scott & White Memorial Hospital and Clinics, Temple, USA
         type:PostalAddress
ImageObject:
      url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
Person:
      name:Cheryl L. Laffer
      affiliation:
            name:Scott & White Memorial Hospital and Clinics
            address:
               name:Scott & White Memorial Hospital and Clinics, Temple, USA
               type:PostalAddress
            type:Organization
      name:Fernando Elijovich
      affiliation:
            name:Scott & White Memorial Hospital and Clinics
            address:
               name:Scott & White Memorial Hospital and Clinics, Temple, USA
               type:PostalAddress
            type:Organization
      email:[email protected]
PostalAddress:
      name:Scott & White Memorial Hospital and Clinics, Temple, USA
      name:Scott & White Memorial Hospital and Clinics, Temple, USA
WebPageElement:
      isAccessibleForFree:
      cssSelector:.main-content

External Links {🔗}(240)

Analytics and Tracking {📊}

Google Tag Manager

Libraries {📚}

Clipboard.js
Prism.js

CDN Services {📦}

Crossref

4.56s.

LINK . SPRINGER . COM {}